Table 1 Baseline demographic profile of patients in the safety population
From: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
| Â | Donepezil 23 mg/d (n = 963) | Donepezil 10 mg/d (n = 471) |
|---|---|---|
Age (years), mean (SD) | 73.9 (8.53) | 73.8 (8.56) |
Gender, n (%) | Â | Â |
   Male | 356 (37.0) | 177 (37.6) |
   Female | 607 (63.0) | 294 (62.4) |
Race, n (%) | Â | Â |
   White | 708 (73.5) | 346 (73.5) |
   Asian/Pacific | 161 (16.7) | 87 (18.5) |
   Hispanic | 67 (7.0) | 26 (5.5) |
   Black | 22 (2.3) | 9 (1.9) |
   Other | 5 (0.5) | 3 (0.6) |
Weight (kg) | Â | Â |
   <55 | 218 (22.6) | 111 (23.6) |
   ≥55 | 744 (77.3) | 360 (76.4) |
   Missing | 1 (0.1) | 0 (0.0) |
Concomitant memantine use, n (%) | Â | Â |
   Memantine | 352 (36.6) | 168 (35.7) |
   None | 611 (63.4) | 303 (64.3) |
Prior donepezil use (weeks) | Â | Â |
   Mean (SD) | 112.2 (108.2) | 104.8 (99.0) |
Range | 9.9-574.6 | 10.4-606.4 |
Baseline MMSE | Â | Â |
   Mean (SD) | 13.1 (4.99) | 13.0 (4.75) |